Key result
Currently available glucose-lowering therapies in diabetes mellitus impact heart failure clinical outcomes, though mortality and hospitalization rates remain high despite intensive glycemic control.
Why the study?
Despite novel therapeutic options and intensive glycaemic control, mortality and hospitalisation rates remain high and HF incidence persists in patients with DM.
Do currently available glucose-lowering therapies improve heart failure clinical outcomes in patients with diabetes mellitus?
Do currently available glucose-lowering therapies improve heart failure clinical outcomes in patients with diabetes mellitus?
Answers are grounded in this paper and cite their sources.
This review summarizes the impact of current glucose-lowering therapies on heart failure outcomes in patients with diabetes mellitus, highlighting alternative pathophysiological mechanisms for therapeutic targeting.
Diabetes mellitus (DM) and heart failure (HF) are comorbid conditions associated with significant morbidity and mortality worldwide. Despite the availability of novel and effective therapeutic options and intensive glycaemic control strategies, mortality and hospitalisation rates continue to remain high and the incidence of HF persists. In this review, we described the impact of currently available glucose-lowering therapies in DM with a focus on HF clinical outcomes. Non-conventional modes of management and alternative pathophysiological mechanisms with the potential for therapeutic targeting are also discussed.
No takes yet. Share an insight, caveat, or question.
Sohrabi et al. (2020) conducted a review in Diabetes mellitus and heart failure. Glucose-lowering therapies was evaluated on Heart failure clinical outcomes. Currently available glucose-lowering therapies in diabetes mellitus impact heart failure clinical outcomes, though mortality and hospitalization rates remain high despite intensive glycemic control.
Synapse has enriched 10 related papers. Consider them for comparative context: